文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

墨西哥青少年和年轻成人百日咳血清流行病学:2012年全国健康与营养调查

Estimating Bordetella pertussis seroprevalence in adolescents and young adults in Mexico using the 2012 National Health and Nutrition Survey (ENSANUT).
PubMed 文献 · Vaccine · 2021-08-28

基于墨西哥2012年全国健康与营养调查(ENSANUT)的概率抽样,检测1581名10-25岁青少年和年轻成人抗百日咳毒素(PT)IgG抗体。总体血清阳性率为3.9%(95%CI: 2.3-6.3),青少年为3.1%(95%CI: 1.9-5.0),年轻成人为4.9%(95%CI: 2.2-11);血清阳性率在性别、社会经济状况、地区和城乡间无显著差异。多数青少年和成人血清阴性,对百日咳易感。

要点

  • 墨西哥10-25岁人群抗PT IgG总体血清阳性率为3.9%(95%CI: 2.3-6.3)。
  • 青少年(10-19岁)血清阳性率为3.1%,年轻成人(20-25岁)为4.9%。
  • 多数青少年和成人血清阴性,对百日咳感染易感。

核心结论

  • 墨西哥青少年和年轻成人中百日咳近期感染负担可观,但多数人血清阴性且易感。
  • 由于墨西哥国家政策不推荐幼儿期后接种百日咳加强疫苗,抗PT IgG血清阳性可合理归因于近期感染。
  • 评估百日咳血清阳性率需谨慎考虑诊断试验阈值解释和所用流行病学模型。

研究设计与样本

  • 基于墨西哥2012年全国健康与营养调查(ENSANUT)的概率抽样调查。
  • 分析1581名受试者血清和数据,包括1102名青少年(10-19岁)和479名年轻成人(20-25岁)。
  • 采用CDC/FDA ELISA检测抗百日咳毒素(PT)IgG抗体。
  • 234份样本子集额外用Bp-IgG PT ELISA试剂盒(EUROIMMUN AG)检测。
  • 使用相应检测试剂盒的阈值判定近期感染或接种。

主要发现

  • 总体抗PT IgG血清阳性率为3.9%(95%CI: 2.3-6.3)。
  • 青少年血清阳性率为3.1%(95%CI: 1.9-5.0),年轻成人为4.9%(95%CI: 2.2-11)。
  • 血清阳性率在性别、社会经济状况、地区或城乡间无显著差异。
  • 与CDC/FDA ELISA相比,EUROIMMUN检测敏感性为76%,特异性为88%。

关键数值与推荐

  • 抗PT IgG血清阳性率总体3.9%(95%CI: 2.3-6.3),青少年3.1%(95%CI: 1.9-5.0),年轻成人4.9%(95%CI: 2.2-11)。
  • EUROIMMUN检测相对CDC/FDA ELISA的敏感性76%,特异性88%。
  • 墨西哥国家政策不推荐幼儿期后接种百日咳加强疫苗。

临床怎么用

  • 在墨西哥青少年和年轻成人中,抗PT IgG血清阳性可提示近期百日咳感染。
  • 血清学评估需注意不同检测试剂盒阈值解释的差异,如EUROIMMUN与CDC/FDA ELISA敏感性76%、特异性88%。
  • 多数青少年和成人血清阴性,提示该人群对百日咳普遍易感,应关注传播风险。

局限性

  • 血清阳性率可能受检测试剂盒阈值解释和流行病学模型选择的影响。
  • 仅234份样本子集用EUROIMMUN试剂盒检测,与CDC/FDA ELISA的比较基于此子集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low vaccination rates and under-detection of pertussis infections in adolescents and young adults have an impact on the transmission of pertussis to infants. In this study, the proportion of adolescents and young adults with IgG antibodies against B. pertussis antigens, representing recent infection or vaccination, was estimated in a population-based probabilistic survey in Mexico. METHODS: Sera and data from 1,581 subjects, including 1,102 adolescents and 479 young adults (10-19 and 20-25 years old, respectively) randomly selected from Mexico's 2012 National Health and Nutrition Survey, were analyzed. IgG antibodies against pertussis toxin (PT) were measured with the CDC/FDA ELISA. A subset of 234 samples was additionally tested with Bp-IgG PT ELISA kit (EUROIMMUN AG, Lubeck, Germany). Threshold values from corresponding test kits were used to identify recent infection or vaccination. RESULTS: Overall anti-PT IgG seroprevalence was 3.9% (95% CI: 2.3-6.3); 3.1% (95% CI: 1.9-5.0) in adolescents, and 4.9% (95% CI: 2.2-11) in young adults. Seroprevalence did not significantly vary by sex, socioeconomic status, region or rural/urban location. Compared to the CDC/FDA ELISA, the EUROIMMUN test showed a 76% sensitivity and 88% specificity. The weighted estimates represent a considerable burden of recent infection in adolescents and young adults; however, most adolescents and adults were seronegative and, therefore, susceptible to pertussis infection. CONCLUSION: Since booster vaccination to B. pertussis after toddlerhood is not recommended in the Mexican national policy, anti-PT IgG seropositivity may be reasonably attributed to recent infection. Assessing pertussis seroprevalence requires careful consideration of the diagnostic test threshold interpretation and epidemiological model used.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Echaniz-Aviles G, García-Cisneros S, Sánchez-Alemán MA, et al. Estimating Bordetella pertussis seroprevalence in adolescents and young adults in Mexico using the 2012 National Health and Nutrition Survey (ENSANUT). Vaccine. 2021. PMID: 34465476. doi:10.1016/j.vaccine.2021.08.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。